EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Ziyu Kuang, Yuansha Ge, Luchang Cao, Xinmiao Wang, Kexin Liu, Jiaxi Wang, Xiaojuan Zhu, Min Wu, Jie Li

Current Treatment Options in Oncology · 2024-08 · 25 (8) · 1038-1054

DOI: 10.1007/s11864-024-01238-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 27.07.2024. Verfasst von Ziyu Kuang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 10053, China. Hauptthemen laut MEDLINE: Cardiotoxicity, Anthracyclines. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Opinion Statement Anthracycline (ANT)-induced cardiotoxicity (AIC) is a particularly prominent form of cancer therapy-related cardiovascular toxicity leading to the limitations of ANTs in clinical practice. Even though AIC has drawn particular attention, the best way to treat it is remaining unclear. Updates to AIC therapy have been made possible by recent developments in research on the underlying processes of AIC. We review the current molecular pathways leading to AIC: 1) oxidative stress (OS) including enzymatic-induced and other mechanisms; 2) topoisomerase; 3) inflammatory response; 4) cardiac progenitor cell damage; 5) epigenetic changes; 6) renin-angiotensin-aldosterone system (RAAS) dysregulation. And we systematically discuss current prevention and treatment strategies and novel pathogenesis-based therapies for AIC: 1) dose reduction and change; 2) altering drug delivery methods; 3) antioxidants, dexrezosen, statina, RAAS inhibitors, and hypoglycemic drugs; 4) miRNA, natural phytochemicals, mesenchymal stem cells, and cardiac progenitor cells. We also offer a fresh perspective on the management of AIC by outlining the current dilemmas and challenges associated with its prevention and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityAnthracyclinesHumansPrecision MedicineAnimalsNeoplasmsOxidative StressDisease ManagementDisease SusceptibilityRenin-Angiotensin SystemBiomarkers

Stichwörter der Autor:innen

AnthracyclineCancerCardiotoxicityChemotherapyDoxorubicinHeart failure

Substanzen

AnthracyclinesBiomarkers

Autor:innen und Institutionen

  • Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 10053, China.
  • Graduate School, Beijing University of Chinese Medicine, Beijing, 10029, China.
  • The 3rd affiliated hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China. zxj8063@yeah.net.
  • Department of Cardiovascular, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 10053, China. wumin@gamyy.cn.
  • Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 10053, China. qfm2020jieli@yeah.net.

Zitieren

APA

Kuang, Z., Ge, Y., Cao, L., Wang, X., Liu, K., Wang, J., Zhu, X., Wu, M., & Li, J. (2024). Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review. Current Treatment Options in Oncology, 25(8), 1038-1054. https://doi.org/10.1007/s11864-024-01238-9

Vancouver

Kuang Z, Ge Y, Cao L, Wang X, Liu K, Wang J, et al. Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review. Current Treatment Options in Oncology. 2024;25(8):1038-1054. doi:10.1007/s11864-024-01238-9

BibTeX
@article{Kuang2024,
  author = {Kuang, Ziyu and Ge, Yuansha and Cao, Luchang and Wang, Xinmiao and Liu, Kexin and Wang, Jiaxi and Zhu, Xiaojuan and Wu, Min and Li, Jie},
  title = {Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {8},
  pages = {1038--1054},
  doi = {10.1007/s11864-024-01238-9}
}
Kostenlos starten →